Although clinical evidence indicates that EGFR-mutant lung cancers rarely benefit from anti-PD-1/PD-L1 immunotherapy5,9,34, recent studies, such as ATLANTIC and IMpower150, have reported more positive results for PD-1/PD-L1 inhibitors in EGFR-mutant lung cancers35,36. This evidence concerns the gene EGFR and lung carcinoma.